CC BY 4.0 · TH Open 2020; 04(04): e300-e302
DOI: 10.1055/s-0040-1719232
Letter to the Editor

Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?

Francesco Marongiu
1  Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
,
Doris Barcellona
1  Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
2  SHRO, Temple University, Philadelphia, Pennsylvania, United States
› Author Affiliations
  

We have read with interest the review article by Bikdeli et al recently published in Thrombosis and Haemostasis on the priority in planning studies on the different anticoagulants in coronavirus disease 2019 (COVID-19) infection.[1] The authors describe the characteristics of both the anticoagulants available today and in the future. Antiplatelets drugs have been also considered.

Surprisingly, fondaparinux (FPX) has reached a lower priority research mean (4.89) than unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) at intermediate (7.82) or therapeutic (7.53) dosage for hospitalized ward and intensive care unit patients.

We believe that properties of these drugs have been overlooked by the scientific panel of the Global COVID-19 Thrombosis Collaborative Group.



Publication History

Publication Date:
16 October 2020 (online)

© .

Georg Thieme Verlag KG
Stuttgart · New York